Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy

Authors:
Nanruoyi Zhou
Search for other papers by Nanruoyi Zhou in
Current site
Google Scholar
PubMed Close
 BA
,
Maria A. Velez
Search for other papers by Maria A. Velez in
Current site
Google Scholar
PubMed Close
 MD
,
Dwight Owen
Search for other papers by Dwight Owen in
Current site
Google Scholar
PubMed Close
 MD
, and
Aaron E. Lisberg
Search for other papers by Aaron E. Lisberg in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 18: Issue 9
Online Publication Date:
Sep 2020
DOI:
https://doi.org/10.6004/jnccn.2020.7640
Restricted access

Disclosures: Dr. Owen has disclosed that he receives grant/research support from BMS, Merck, Palobiofarma, and Genentech. Dr. Lisberg has disclosed that he has received grant/research support from Daiichi Sankyo, Calithera Biosciences, AstraZeneca, Dracen Pharmaceuticals, and WindMIL; he is a scientific advisor/consultant for AstraZeneca, Bristol-Myers Squibb, Leica Biosystems, Jazz Pharmaceuticals, Novocure, Pfizer, and MorphoSys; and his spouse is employed by and owns stock in Boston Scientific. The remaining authors have disclosed that they have no financial interests, arrangement affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.

Correspondence: Aaron E. Lisberg, MD, 2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404. Email: alisberg@mednet.ucla.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small cell lung cancer. N Engl J Med 2015;373:1627–1639.

  • 2.

    Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–135.

  • 3.

    Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016;375:1823–1833.

  • 4.

    Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 2016;21:1230–1240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Kichenadasse G, Miners JO, Mangoni AA, et al. Multiorgan immune-related adverse events during treatment with atezolizumab. J Natl Compr Canc Netw 2020;18:1191–1199.

  • 6.

    Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837–1846.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017;35:2781–2789.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Spigel DR, Chaft JE, Gettinger S, et al. FIR: Efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with NSCLC. J Thorac Oncol 2018;13:1733–1742.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Dupont R, Bérard E, Puisset F, et al. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study [published online November 5, 2019]. OncoImmunology, doi:10.1080/2162402X.2019.1682383

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Kartolo A, Sattar J, Sahai V, et al. Predictors of immunotherapy-induced immune-related adverse events [published online November 2, 2018]. Curr Oncol, doi:10.3747/co.25.4047

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Cortellini A, Chiari R, Ricciuti B, et al. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer 2019;20:237–247.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Nigro O, Cortellini A, Giusti R, et al. Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. Ann Oncol 2019;30 (Suppl 11). doi:10.1093/annonc/mdz449.009

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Okada N, Kawazoe H, Takechi K, et al. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther 2019;41:Abstract X120.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Singh P, Brito A, Abdulnour REE, et al. Defining real-world criteria for immune-related adverse events (irAEs) [abstract]. J Clin Oncol 2019;37(Suppl):Abstract e14172.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Abu-Sbeih H, Tang T, Ali FS, et al. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol 2018;1:7–18.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 2019;145:479–485.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 2017;82:34–44.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Owen DH, Wei L, Bertino EM, et al. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer 2018;19:e893–900.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Lisberg A, Tucker DA, Goldman JW, et al. Treatment related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center [published online January 1, 2018]. Cancer Immunol Res, doi:10.1158/2326-6066.CIR-17-0063

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    von Itzstein MS, Khan S, Gerber DE. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem 2020;66:779–793.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017;28:2377–2385.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 2019;25:551–557.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors [published November 15,2019]. J Immunother Cancer, doi:10.1186/s40425-019-0805-8

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 2018;378:2078–2092.

  • 26.

    Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017;377:1919–1929.

  • 27.

    Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116–1127.

  • 28.

    Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714–1768.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Thompson JA, Schneider BJ, Brahmer JR, et al. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities, Version 1.2020. Accessed August 7, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 30.

    Davis EJ, Salem JE, Young A, et al. Hematologic complications of immune checkpoint inhibitors. Oncologist 2019;24:584–588.

Copyright:
Copyright © 2020 by the National Comprehensive Cancer Network 2020
Page Numbers:
4
Article Category:
Other
Print Publication Date:
01 Sep 2020
Online Publication Date:
Sep 2020

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 5924 225 27
PDF Downloads 2610 166 12
EPUB Downloads 0 0 0